The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
350 jobs Number of planned job creations
Announcement Date
6 September 2010
Employment effect (start)
1 September 2010
Foreseen end date
1 September 2012
Description
Teva Czech Industries (formerly known as IVAX and Galena), an important pharmaceutical company, has announced the creation of 350 new jobs with the launch of a new plant located in Opava on 1 September 2010. The new facility produces tablets and gelatin capsules for US market. The company also announced a further investment of about CZK 500 million that will bring another 300 new jobs within two years. At present, Teva employs over 1,200 people. For previous restructuring see here.
Sources
6 September 2010: Novinky
Citation
Eurofound (2010), Teva Czech Industries, Business expansion in Czechia, factsheet number 70907, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/70907.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
